Novartis, GlaxoSmithKline enter pipeline boosting deals

Share this article:
Novartis and GlaxoSmithKline announced separate deals with smaller biotech firms to ramp up their respective product pipelines. Novartis agreed to acquire NeuTec Pharma, a UK biopharmaceutical company specializing in hospital “super-bug” anti-infectives for $569 million. NeuTec’s Mycograb is awaiting European approval. Novartis said it plans to submit the drug for US regulatory approval in 2009. Another NeuTec drug, Aurograb, is scheduled for European and US regulatory filing in 2010. Meanwhile, GlaxoSmithKline agreed to pay Galapagos an upfront fee of $5.1 million plus milestone payments if two of the latter’s osteoarthritis products are launched. As part of the deal, GlaxoSmithKline will have exclusive options to further develop and commercialize these compounds on a worldwide basis.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.